Erasca Inc (ERAS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Erasca Inc (ERAS) has a cash flow conversion efficiency ratio of -0.070x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.38 Million) by net assets ($393.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Erasca Inc net asset quality index to measure how much of total assets are equity-financed.
Erasca Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Erasca Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Erasca Inc (ERAS) long-term investment share to see how much of total assets are deployed in long-term investments.
Erasca Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Erasca Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sigma Foods, S.A.B. de C.V.
MX:SIGMAFA
|
0.362x |
|
Inner Mongolia MengDian HuaNeng Thermal Power Corp Ltd
SHG:600863
|
0.081x |
|
Uipath Inc
NYSE:PATH
|
0.088x |
|
Axfood AB
ST:AXFO
|
0.286x |
|
Beijing Jingneng Power Co Ltd
SHG:600578
|
0.106x |
|
Shanghai 2345 Network Holding Group
SHE:002195
|
0.028x |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
0.327x |
|
AB Sagax (publ)
ST:SAGA-B
|
0.013x |
Annual Cash Flow Conversion Efficiency for Erasca Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Erasca Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Erasca Inc (ERAS) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $325.17 Million | $-95.45 Million | -0.294x | -13.62% |
| 2024-12-31 | $423.50 Million | $-109.42 Million | -0.258x | +19.16% |
| 2023-12-31 | $316.69 Million | $-101.22 Million | -0.320x | -27.47% |
| 2022-12-31 | $411.85 Million | $-103.26 Million | -0.251x | -43.80% |
| 2021-12-31 | $456.53 Million | $-79.60 Million | -0.174x | -160.80% |
| 2020-12-31 | $-113.98 Million | $-32.69 Million | 0.287x | -62.41% |
| 2019-12-31 | $-13.60 Million | $-10.38 Million | 0.763x | -- |
About Erasca Inc
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid … Read more